Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 16/20 | 0.72 |
| ▸ | GSTM2 | P28161 | 16/20 | 0.72 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296944 | 0.86 | GSTP1 (0.77) | GSTP1GSTM2IDO1 | |
| SCHEMBL297913 | 0.84 | GSTP1 (1.00) | GSTP1GSTM2IDO1 | |
| SCHEMBL16907678 | 0.82 | GSTP1 (0.48) | GSTP1GSTM2IDO1 | |
| SCHEMBL18878879 | 0.81 | IDO1 (0.74) | GSTP1GSTM2IDO1 | |
| SCHEMBL301085 | 0.79 | GSTP1 (0.57) | GSTP1GSTM2IDO1 | |
| SCHEMBL16907488 | 0.79 | GSTP1 (0.42) | GSTP1GSTM2IDO1 | |
| SCHEMBL26425058 | 0.79 | GSTP1 (0.64) | GSTP1GSTM2 | |
| SCHEMBL22705025 | 0.78 | GSTP1 (0.54) | GSTP1GSTM2IDO1 | |
| SCHEMBL22689399 | 0.76 | GSTP1 (0.58) | GSTP1GSTM2 | |
| SCHEMBL611015 | 0.76 | KMT2A (0.72) | GSTM2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2012-05-17 | — | — | US | claimed |
| EP-2427442-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | claimed |
| WO-2010128156-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2010-11-11 | — | — | WO | claimed |
| WO-2015104433-A1 | BENZO[C][1,2,5]OXADIAZOLE DERIVATIVES FOR TREATING DISEASES CAUSED BY HELICOBACTER | UNIVERSIDAD DE ZARAGOZA (ES) | 2015-07-16 | — | — | WO | disclosed |
| US-8367840-B2 | Composition for treating infectious diseases caused by Helicobacter | UNIVERSIDAD DE ZARAGOZA (ES) | 2013-02-05 | — | — | US | disclosed |
| US-8367840-B2 | Composition for treating infectious diseases caused by Helicobacter | UNIVERSIDAD DE ZARAGOZA (ES) | 2013-02-05 | — | — | US | disclosed |
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2427442-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427442-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128156-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128156-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100063296-A1 | COMPOSITION FOR TREATING INFECTIOUS DISEASES CAUSED BY HELICOBACTER | UNIVERSIDAD DE ZARAGOZA (ES) | 2010-03-11 | — | — | US | disclosed |
| US-20100063296-A1 | COMPOSITION FOR TREATING INFECTIOUS DISEASES CAUSED BY HELICOBACTER | UNIVERSIDAD DE ZARAGOZA (ES) | 2010-03-11 | — | — | US | disclosed |
| EP-2130824-A1 | COMPOSITION FOR TREATING INFECTIOUS DISEASES CAUSED BY HELICOBACTER | UNIVERSIDAD DE ZARAGOZA (ES) | 2009-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TENT4B, IRF3, MAVS | GSTP1 1679/4885GSTM2 2265/4885IDO1 196/4885 |
| US-20100063296-A1 | COMPOSITION FOR TREATING INFECTIOUS DISEASES CAUSED BY HELICOBACTER | CYB5R3, C1R, CBR3 | GSTP1 825/4885GSTM2 796/4885IDO1 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.